The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients
Therapeutic Advances in Drug Safety · 2026-04 · 17
DOI: 10.1177/20420986251414591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Drug Safety, online erschienen am 22.04.2026. Verfasst von Stefania Crucitta und 17 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib have rapidly become an established oral treatment for patients with ER+, HER2− locally advanced or metastatic breast cancer. The use of the oral route offers convenience and flexibility to the patient; however, the co-administration of proton pump inhibitors (PPIs) to mitigate gastrointestinal adverse events induced by anticancer treatments may decrease drug solubility, bioavailability, and potentially impact treatment efficacy.
Objectives
The present study was aimed at investigating whether PPIs may affect the progression-free survival (PFS) of patients treated with abemaciclib.
Design
Multicenter observational cohort study on clinical data collected retrospectively.
Methods
Patients with ER-positive/HER2-negative mBC candidates for a first-line treatment with abemaciclib as per clinical practice were enrolled. Patients were classified as “no concomitant PPIs” or “concomitant PPIs” if PPI administration covered not less than 2/3 of the treatment period with abemaciclib. All clinical interventions were made according to clinical practice.
Results
One hundred eight patients were enrolled in this study; 66 belonged to the “no concomitant PPIs” group and 42 to the “concomitant PPIs” group. No statistically significant difference in PFS was found between the two groups ( p = 0.77). Likewise, no difference in PFS was observed in endocrine-sensitive or -resistant mBC in the presence or absence of concomitant PPI treatment. No correlation with adverse events, including hematological or gastrointestinal toxicities, was found.
Conclusion
This study demonstrates that the administration of PPIs to patients treated with abemaciclib is not associated with clinically significant drug–drug interactions on PFS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
- Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust of Verona, Verona, Italy.
- Department of Experimental Medicine, University of Salento, Lecce, Italy.
- Division of Medical Oncology, University of Modena and Reggio Emilia, Modena, Italy.
- Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.
ORCID-Profile: Stefania Crucitta, Romano Danesi, Marzia Del Re
Zitieren
APA
Crucitta, S., Cinacchi, P., Bargagna, I., Biondani, P., Giontella, E., Palleschi, M., Omarini, C., Belluzzi, L., Angelini, L., Meattini, I., Visani, L., Stucci, S., Porta, C., Fontana, A., De Giorgi, U., Fogli, S., Danesi, R., & Del Re, M. (2026). The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients. Therapeutic Advances in Drug Safety, 17. https://doi.org/10.1177/20420986251414591
Vancouver
Crucitta S, Cinacchi P, Bargagna I, Biondani P, Giontella E, Palleschi M, et al. The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients. Therapeutic Advances in Drug Safety. 2026;17. doi:10.1177/20420986251414591
BibTeX
@article{Crucitta2026,
author = {Crucitta, Stefania and Cinacchi, Paola and Bargagna, Irene and Biondani, Pamela and Giontella, Elena and Palleschi, Michela and Omarini, Claudia and Belluzzi, Lorenzo and Angelini, Lucia and Meattini, Icro and Visani, Luca and Stucci, Stefania and Porta, Camillo and Fontana, Andrea and De Giorgi, Ugo and Fogli, Stefano and Danesi, Romano and Del Re, Marzia},
title = {The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients},
journal = {Therapeutic Advances in Drug Safety},
year = {2026},
volume = {17},
doi = {10.1177/20420986251414591}
}
EUVIMED